Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015
Antipsychotics and amotivation.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- Sex-specific effects of the atypical antipsychotic risperidone on performance in a risky decision-making task.Behavioural brain research · 2027Article
- Dysfunctions of Reward Motivation Adaptation in Patients With Schizophrenia.PsyCh journal · 2025Article
- Psychological side effects of antipsychotic medication after remission from first-episode psychosis: a HAMLETT ecological momentary assessment study.Psychological medicine · 2025Article
- Molecular, physiological and functional features underlying antipsychotic medication use related cortical thinning.Translational psychiatry · 2025Article
- Clinical implications of admission anemia for electroconvulsive therapy planning in adolescent major depressive disorder: identifying vulnerable subgroups with poorer response.Frontiers in psychiatry · 2025Article
- Interaction between catechol-O-methyltransferase Val/Met polymorphism and cognitive reserve for negative symptoms in schizophrenia.World journal of psychiatry · 2024Article
- Determinants and outcomes of health-promoting lifestyle among people with schizophrenia.BMC psychiatry · 2024Article
- Resting-state functional connectivity indicators of risk and resilience for self-harm in adolescent bipolar disorder.Psychological medicine · 2023Article
- The crosstalk between 5-HTNeuropharmacology · 2023Review
- Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study.Frontiers in psychiatry · 2023Article
- A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.British journal of clinical pharmacology · 2022Article
- Biopsychology of Physical Activity in People with Schizophrenia: An Integrative Perspective on Barriers and Intervention Strategies.Neuropsychiatric disease and treatment · 2022Article
- Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity.Molecular psychiatry · 2021Article
- Brain activity and connectivity differences in reward value discrimination during effort computation in schizophrenia.European archives of psychiatry and clinical neuroscience · 2021Article
- Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders.Frontiers in psychiatry · 2021Review
- Emerging roles of striatal dopamine D2 receptors in motivated behaviour: Implications for psychiatric disorders.Basic & clinical pharmacology & toxicology · 2020Review
- The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia.European archives of psychiatry and clinical neuroscience · 2019Article
- Blockade of muscarinic acetylcholine receptors facilitates motivated behaviour and rescues a model of antipsychotic-induced amotivation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Article
- Oxygen responses within the nucleus accumbens are associated with individual differences in effort exertion in rats.The European journal of neuroscience · 2018Article
- HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice.Neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Antipsychotic drugs are thought to produce secondary negative symptoms, which can also exacerbate primary negative symptoms. In the present study, we examined whether motivational deficits in particular were related to antipsychotic treatment in patients with schizophrenia in a dose-dependent manner. Five hundred and twenty individuals with schizophrenia who were receiving antipsychotic monotherapy for at least 6 months and followed prospectively were included in the present study. Participants were receiving one of five antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone), and analyses were conducted for patients receiving each drug separately. Analysis of covariance models were constructed to examine the effect of antipsychotic dose on level of motivational impairment, controlling for selected demographic and clinical variables (eg, positive symptoms). Level of motivation, or deficits therein, were evaluated using a derived measure from the Quality of Life Scale, and in addition with scores derived from the Positive and Negative Syndrome Scale. Antipsychotic dose was not related to the level of amotivation for any of the medications examined. Moreover, severity of sedation was not significantly related to the degree of amotivation. One hundred and twenty-one individuals were identified as antipsychotic-free at baseline, and after 6 months of antipsychotic treatment, no change in motivation was found. Chronic treatment with antipsychotics does not necessarily impede or enhance goal-directed motivation in patients with schizophrenia. It is possible that the negative impact of antipsychotics in this regard is overstated; conversely, the present results also indicate that we must look beyond antipsychotics in our efforts to improve motivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.